

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/308740276>

Hepatocyte growth factor improves direct reprogramming of fibroblasts towards endothelial progenitor...

Article · September 2016

DOI: 10.7603/s40730-016-0045-1

CITATIONS

0

READS

31

7 authors, including:



Phuc Van Pham

Ho Chi Minh City University of Science

142 PUBLICATIONS 473 CITATIONS

SEE PROFILE



Ngoc Bich Vu

Ho Chi Minh City University of Science

37 PUBLICATIONS 153 CITATIONS

SEE PROFILE



Hoa Nguyen Trong

Ho Chi Minh City University of Science

3 PUBLICATIONS 3 CITATIONS

SEE PROFILE



Mai Truong

Ho Chi Minh City University of Science

3 PUBLICATIONS 2 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Orthopedic regeneration [View project](#)



Clinical application of adipose derived stem cells for chronic obstructive pulmonary disease [View project](#)

All content following this page was uploaded by [Phuc Van Pham](#) on 29 September 2016.

The user has requested enhancement of the downloaded file. All in-text references [underlined in blue](#) are added to the original document and are linked to publications on ResearchGate, letting you access and read them immediately.

Hepatocyte growth factor improves direct reprogramming of fibroblasts towards endothelial progenitor cells via ETV2 transduction

Phuc Van Pham^{1,*}, Ngoc Bich Vu¹, Mai Thi-Hoang Truong¹, Oanh Thuy Huynh¹, Hoa Trong Nguyen¹, Hieu Liem Pham², Ngoc Kim Phan¹

¹Laboratory of Stem Cell Research and Application, University of Sciences, Vietnam National University, Ho Chi Minh City, Viet Nam

²Department of Plastic and Aesthetic Surgery, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

*Corresponding author: pvphuc@hcmuns.edu.vn

Received: 15 Aug 2016 / Accepted: 22 Sep 2016 / Published online: 29 Sep 2016

©The Author(s) 2016. This article is published with open access by BioMedPress (BMP)

Abstract— Introduction: Human fibroblasts can be differentiated into endothelial progenitor cells by direct reprogramming via ETV-2 transfection. Previously, we have shown that the efficacy of direct reprogramming can be enhanced by hypoxia treatment. In this study, we aim to investigate whether the efficacy of direct reprogramming of fibroblasts into EPCs via Ets variant gene 2 (ETV2) transfection can be increased with hepatocyte growth factor (HGF) treatment. **Methods:** Foreskin-derived fibroblasts were cultured in standard medium (DMEM/F12 supplemented with fetal bovine serum). They were then transduced with a viral vector expressing ETV2 in culture medium supplemented with HGF. The transduced fibroblasts were cultured in endothelial cell medium supplemented with HGF for 28 days. The efficacy of direct reprogramming was evaluated based on expression of CD31 and VEGFR2 markers by transduced cells. Phenotypic and functional characterization of induced EPCs were also confirmed by expression of particular genes and *in vitro* angiogenesis assays. **Results:** Our results showed that HGF significantly increased the efficacy of direct reprogramming of fibroblasts towards EPCs via ETV2 transcription factors; efficiency increased from $5.41 \pm 1.51\%$ for ETV2 transduction alone to $12.31 \pm 2.15\%$ for ETV2 transduction combined with HGF treatment. **Conclusion:** These findings suggest the rationale for combined use of ETV2 and HGF in direct *in vitro* reprogramming of fibroblasts into EPCs.

Keywords: ETV2, direct reprogramming, hepatocyte growth factor, endothelial progenitor cell, fibroblasts, pluripotent stem cells

INTRODUCTION

Endothelial progenitor cells (EPCs) are an important cell source for regenerative medicine (Kalka et al., 2000; Kondo et al., 2003) as well as tissue engineering (Urbich and Dimmeler, 2004). Although EPCs can be isolated from several sources (e.g. bone marrow (Asahara et al., 1999; Takahashi et al., 1999), peripheral blood, umbilical cord blood and adipose tissue), the percentage of EPCs obtained from these sources are extremely low. Therefore, it is important to have another source or strategy to yield a greater quantity of EPCs.

One strategy to yield EPCs involves the *in vitro* differentiation of pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (PSCs), into EPCs. Previous studies have shown that it is feasible to differentiate ESCs into EPCs (Ferreira et al., 2007; Levenberg et al., 2002; Vittet et al., 1996; Wang et al., 2007). The differentiated cells are capable of forming capillary-like structures *in vitro* as well as exhibiting therapeutic effects in animals (Hirashima et al., 1999; Wang et al., 2007). However, ESCs have faced some ethical issues with regard to isolation procedures. Therefore, less focus

has been placed on differentiation of ESCs into EPCs; in lieu of that, there has been greater interest in differentiation of induced PSCs into EPCs. Notably, induced PSCs are pluripotent stem cells which are produced by reprogramming of the genome with certain factors. The first publication about induced PSCs was reported by Yamanaka et al. in 2006 (Takahashi and Yamanaka, 2006). The authors showed that induced PSCs were produced by skin fibroblasts after transduction with 4 factors: Oct-3/4, cMyc, Klf4 and Sox-2. The induced PSCs were also successfully differentiated into EPCs (Choi et al., 2009). However, the biggest limitation related to use of differentiated EPCs from induced PSCs or ESCs has been tumor formation from residual ESCs or induced PSCs inside the differentiated cells. As a way to overcome the limitation of *in vitro* differentiation of PSCs into EPCs, direct reprogramming strategies have now garnered greater consideration.

The first effort towards direct reprogramming of fibroblasts to EPCs was performed by Margariti et al. (Margariti et al., 2012). They developed a method to generate partial-induced PSCs by transferring four reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) to human fibroblasts (HFs) for 4 days. These partial-induced PSCs were capable of differentiating into endothelial cells in response to defined media and culture conditions (Margariti et al., 2012). In the defined solutions, endothelial cells could not form tumors. However, these EPCs also expressed oncogenes, such as *Sox-2*. To resolve this, in subsequent studies by Li et al. and Han et al, the *Sox-2* gene was removed using a revised version of the procedure from Margariti et al. Moreover, the authors used two genes (*Oct4* and *Klf4*) in combination with soluble factors (Li et al., 2013) or *Foxo1*, *Er71*, *Klf2*, *Tal1* and *Lmo2* (Han et al., 2014).

There are have been limitations to the initial studies mentioned above. Firstly, the authors used many factors to convert fibroblasts into EPCs, making the procedure more complicated. Secondly, the efficacy of the procedure was very low. To conduct the direct reprogramming procedure, the Ets variant gene 2 (ETV2) was recently used as a single factor to induce direct reprogramming of fibroblasts into EPCs (Lee et al., 2014; Morita et al., 2015). ETV2 is a master gene that regulates various signaling pathways and functions and is an essential regulator of vasculogenesis and hematopoiesis (Shi et al., 2014), cardiac development (Schupp et al., 2014) and

vascular regeneration (Park et al., 2016). However, direct reprogramming via ETV2 transduction has been low (about 1 %) (Morita et al., 2015). We have tried to improve this efficacy by treatment with hypoxia (Van Pham et al., 2016). Using the hypoxia approach, the efficacy of direct reprogramming of fibroblasts into EPCs by single vector ETV2 increased to 3-4% (Van Pham et al., 2016). Although the efficacy of the procedure was significantly increased, the percentage of reprogrammed EPCs was still low. Therefore, in this study, we aimed to improve the efficacy of epigenetic reprogramming of fibroblasts into EPCs using single vector ETV2 in combination with hepatocyte growth factor (HGF) treatment.

MATERIALS-METHODS

Isolation and culture of fibroblasts from foreskin

Human foreskin was collected at hospitals from donors after consent. At the laboratory, foreskin was washed twice with PBS, cut into small fragments and cultured in DMEM/F12 supplemented with 10% FBS at 37°C, 5% CO₂ condition. After 5 days, the culture was observed to evaluate the migration of fibroblasts from the fragment. After 20 days, the cultures were sub-cultured to promote fibroblast proliferation. The fibroblasts at the 3rd passage were assessed for expression of CD90 and vimentin by flow cytometry and were used for subsequent experiments. Human umbilical vein endothelial cells (HUVECs) were purchased from Life Technologies, Inc. (code number C0035C; Carlsbad, CA).

Production of ETV2-expressing viral vector

Production of the ETV2-expressing viral vector was performed as described in previous studies (Van Pham et al., 2016). Briefly, the human ETV2 expression vector (pF1KB9707) was purchased from Addgene, Inc. (Cambridge, MA). ETV2 was cloned into the vector backbone pSIN4-EF1alpha-IRES-Puro (Plasmid #61061; Addgene, Inc.) to generate pSIN4-EF1a-ETV2-IRES-Puro. All of the coding sequences in the expression vector were confirmed using a GenomeLab System (Beckman Coulter, Brea, CA, USA). The ETV2 vector was then transfected into HEK293T cells along with pCMV-VSV-G-RSV-Rev and pCMV-dR8.2 (Addgene). Eighteen hours after transfection, the medium was replaced with fresh culture medium, and 48 h later the lentivirus-containing medium was

collected, passed through a 0.45- μ m filter and concentrated using centrifugation ($8400 \times g$ at 4 °C for 16 h). The lentivirus pellets were resuspended in PBS at 10^7 IFUs/mL.

Transduction of ETV2 to fibroblasts

Three 12-well plates were seeded with fibroblasts at 7×10^4 cells per well. The plates were divided into 3 groups: 1) "control" (cells not transduced with viral vector), 2) "ETV2" (cells transduced with ETV2 viral vectors), and 3) "ETV2+HGF" (cells transduced with ETV2 viral vector combined with 10 ng/mL HGF in culture medium). After 24 h of incubation, 10 μ L concentrated lentivirus particles with 5 μ g/mL protamine were added into each well of the ETV2 and ETV2+HGF groups. Another 48 h later, cells were washed twice with PBS and then cultured in 6-cm dishes coated with Cellstart (Life Technologies, Inc.). Cells in the ETV2 group were plated in EGM-2 medium and cells in the ETV2+HGF group was plated in EGM-2 medium supplemented with 10 ng/mL HGF (Life Technologies).

Flow cytometry and cell sorting

To evaluate the percentage of CD31+VEGFR2+ cells in the 3 groups (control, ETV2 and ETV2+HGF), cells were collected after 14 days and 28 days by trypsinization with trypsin/EDTA (0.04% EDTA). The cells were resuspended in PBS containing 2 % FBS and 2 mM EDTA, and then stained with fluorochrome-labeled mAbs for 20 min on ice. Two kinds of mAbs were used: anti-human CD31-FITC and anti-human VEGFR2-PE (BD Biosciences, San Jose, C). The expression of these markers were analyzed by a FACSCalibur flow cytometer (BD Biosciences). At day 28, after analysis the CD31+VEGFR2+ cells in the ETV2 and ETV2+HGF groups were sorted using a FACSJazz cell sorter (BD Biosciences). These CD31+VEGFR2+ cells were used for further assays.

Real-time RT-PCR

The sorted CD31+VEGFR2+ cells were used in real-time reverse transcriptase (RT)-PCR. Total RNA was extracted using Trizol according to the manufacturer's instructions. PCR analysis was performed using one-step real-time RT-PCR and the SYBR® Green Quantitative RT-qPCR Kit (Sigma-Aldrich, St. Louis, MO) on a Realplex Mastercycler (Eppendorf, Hamburg, Germany). Relative gene expression levels were normalized by comparison to GAPDH. Gene-specific primer pairs are presented in **Table 1**.

Table 1. Gene-specific primers used for quantitative RT-PCR

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
<i>EFNB2</i>	TCCTCAACTGTGCCAAA CCAGACCAA	AGGCCCTCCAAAGACCCA TTTGATGT
<i>EPHB4</i>	AAGAAAGTTTCGCAGC CGCTGGCTTT	TCATGTGCTGGACTGCGC CAAGATT
<i>HEY1</i>	AAATGCTGCATACGGC AGGAGGGAAA	ATAACGCGCAACTTCTGCC AGGCAT
<i>JAG1</i>	TTTGGAGCGACCTGTGT GGATGAGA	TGGTGATGCAAGGTCTCCC TGAAACT
<i>NR2F2</i>	GGACCACATACGGATC TTCCAAGAGCAA	TTTCTGCAAGCTTTCCAC ATGGGCT
<i>NRP2</i>	AGGAGCCCTGTGGTTGG ATGTATGA	TGTCACTCTGCAGCCGCAA GAAAT
<i>PROX1</i>	ACCCGTTATCCAGCTC CAATATGCT	ATCGTTGATGGCTTGACGT GCGTA
<i>SOX18</i>	TGAACGCCTTCATGGTG TGGGCAA	CGCGTTCAGCTCCTCCAC GCTTT

Capillary-like structure formation assay

The sorted CD31+VEGFR2+ cells were used in capillary-like formation assay. Cells from the ETV2 and ETV2+HGF groups at day 28 were seeded on 96-well flat-bottom plates coated with 30 μ L Matrigel (Life Technologies) and cultured in EGM-2 medium at 2×10^4 cells/well. Eighteen hours after incubation, capillary-like structures were observed under an Axiovert microscope (Carl-Zeiss, Oberkochen, Germany).

Statistical analysis

Statistical analyses of all endpoints were performed using the two-sided Student's *t* test or one-way analysis of variance. All data are presented as mean \pm SD. $p < 0.05$ was considered statistically significant. Data were analyzed with GraphPad Prism 6.0 software.

RESULTS

Culture and characterization of foreskin-derived fibroblasts

The fibroblasts started to migrate from the fragments at day 5. The cells proliferated over 21 days and the cell population was continuously sub-cultured until the 3rd passage to yield a homogenous cell population (**Fig. 1A**). Fibroblast phenotype was confirmed by expression of CD90 (**Fig. 1B**) and vimentin (**Fig. 1C**). The results showed that 100% cells expressed both CD90 and vimentin.




Figure 1. In vitro culture of dermal fibroblasts. The fibroblasts migrated from the fragments from day 5 and became homogenous after 3 passages of sub-culture (A); the cells were confirmed as fibroblasts by assessment of CD90 (B) and vimentin expression (C).

Expression of CD31 and VEGFR2 in transduced fibroblasts

The sub-population with the CD31⁺VEGFR2⁺ phenotype was identified by flow cytometry. The results are represented in Fig. 2. After 14 days, the percentage of the CD31⁺VEGFR2⁺ cell population was 4.01±2.12%, 2.81±1.51%, and 0% in the control, ETV2 and ETV2+HGF groups, respectively (Fig. 2A). There

was no significantly difference between ETV2 and ETV2+HGF groups. However, after 28 days there was a significant difference in the CD31⁺VEGFR2⁺ population of the control, ETV2 and ETV2+HGF groups; the percentage was 12.31±2.15%, 5.41±1.51%, and 0% for control, ETV2 and ETV2+HGF groups, respectively (Fig. 2B).




Figure 2. Detection of CD31⁺VEGFR2⁺ cells in transduced fibroblasts. The CD31⁺VEGFR2⁺ cell population seen in ETV2+HGF group at day 0 (before transduction, A), at day 14 (B) and day 28 (C).

Profile of gene expression related to EPCs

The CD31⁺VEGFR2⁺ cells were sorted from transduced cells of the ETV2 or ETV2+HGF groups. The purified cells were evaluated for expression of *NRP2*, *NR2F2*, *EPHB4*, *JAG1*, *EFNB2*, *HEY1*, *PROX2*, and *SOX18* (all these genes are expressed in induced EPCs). The results showed that expression of these genes significantly increased in both ETV2 and

ETV2+HGF groups, compared to the non-transduced (control) group. However, the expression of these genes were lower than that typically expressed by HUVECs. Although the expression of these genes were different between the ETV2 and ETV2+HGF 2 groups, the differences were non-significant after normalization to GAPDH ($p > 0.05$), except for the *EFNB2* gene (Fig. 3).




Figure 3. Expression of some genes in induced cells related to endothelial cells. (A) *NRP2*, *NR2F2*, *EPHB4*, *JAG1*, and *SOX18*. (B) *EFNB2*, *HEY1*, and *PROX2*. Generally almost endothelial cell-related genes significantly increased in ETV2 transduced fibroblasts in both ETV2 alone and ETV2+HGF.

The capillary like structure formation of induced EPCs

To evaluate the biological activities of induced EPCs in some groups, the sorted CD31⁺VEGFR2⁺ cells were cultured in matrigel to determine the capillary-like structure formation. After 18 h of incubation,

CD31⁺VEGFR2⁺ cells from both the ETV2 and ETV2+HGF groups could form capillary-like structures similar to HUVECs (Fig. 4). However, the fibroblasts could not form these structures.




Figure 4. Capillary-like network on Matrigel by cells in groups. (A) HF cells could not form the capillary-like network. (B) ETV2 transduced HF cells in both ETV2 transduction alone and ETV2+HGF, successfully forming the capillary-like network (B-C).

DISCUSSION

EPCs are an important cell source for regenerative medicine and tissue engineering. EPCs can be used to treat ischemia-related diseases as well as to produce blood vessels. However, the source of EPCs in some tissues are so low and very difficult to culture and proliferate *in vitro*. This study provided a new method to efficiently produce EPCs *in vitro* for applications through direct reprogramming of fibroblasts.

In a previous study, Morita et al. (2014) demonstrated success in directly converting fibroblasts into EPCs using a single gene factor (ETV2). Recently, the

efficacy of this procedure was improved upon with hypoxia treatment. Using a hypoxic condition, the efficacy of the procedure significantly increased from 3% to 7% (Van Pham et al., 2016). In the study herein, we improved the procedure further via treatment of fibroblasts with HGF during the converting procedure.

This study also confirms the roles of HGF in endothelial differentiation and reprogramming. The reprogrammed cells under HGF treatment had same similar properties as the control. They exhibited not only EPC phenotype but also *in vitro* function. They expressed the particular markers of EPCs (e.g. CD31

and VEGFR2). CD31 and VEGFR2 are two popular markers of EPCs which have been used to identify and confirm EPC populations in several previous studies. These markers are also expressed in EPCs derived from bone marrow, peripheral blood and umbilical cord blood (Amini et al., 2012; Cherqui et al., 2006; Hristov et al., 2003; Masek and Sweetenham, 1994; Mead et al., 2008). The reprogrammed cells could also exhibit capillary-like structure formation *in vitro* (Mead et al., 2008). Overall, in the conditions with ETV2 transduction alone or ETV2+HGF, induced EPCs exhibited the functional EPC phenotypes.

However, quantitative analysis showed that the percentage of the CD31+VEGFR2⁺ cell population in the ETV2+HGF group was significant higher than that of the ETV2 group. Our results confirm that HGF supplement in the endothelial cell culture medium increases the percentage of induced EPCs. The mechanism of HGF effects on the direct reprogramming of fibroblasts toward induced EPCs via ETV2 was not investigated in this study. However, based on some previous studies examining the roles of HGF, there are some suggestions as to the mechanism of HGF in our procedure.

HGF efficiently stimulates the proliferation of induced EPCs. With this mechanism, the initial direct reprogramming in the ETV2 and ETV2+HGF groups could be similar. However, after 21 days under HGF treatment condition, HGF may stimulate proliferation of induced EPCs. Thus, at day 21 the percentage of induced EPCs in the ETV2+HGF group was higher than that of the HGF group and that of the ETV2 group. Indeed, Song et al. (2009) transfected HGF into EPCs and showed that transfection of EPCs with HGF enhanced the proliferative, migratory and angiogenic capabilities, and promoted the activation of ERK1/2 without affecting its expression (Song et al., 2009). Interestingly, in the study of Zhu et al. (2010), the authors determined that HGF secreted from smooth muscle cells played a role in the regulation of EPC differentiation, migration and proliferation (Zhu et al., 2010). They also showed that exogenous recombinant HGF markedly up-regulated eNOS mRNA expression in EPCs and promoted EPC migration and proliferation, while bearing no significant changes in KDR and CD31 mRNA expression (Zhu et al., 2010).

In another study, HGF was shown to be the factor responsible for inducing the pro-angiogenic phenotype and mobilizing EPCs by activating Nox2

(Schroder et al., 2011). Furthermore, HGF protected EPCs from damage of low-density lipoprotein cholesterol via the PI3K/Akt signaling pathway (Yu et al., 2010), prevented advanced glycation end product-induced injury (Zhou et al., 2006), prevented oxidative stress through a PI3K/Akt-dependent pathway (Zhou et al., 2009), and attenuated angiotensin II-induced endothelial progenitor cell senescence (Sanada et al., 2009). HGF *in vivo* can induce angiogenesis through mobilizing EPCs (Ishizawa et al., 2004). Collectively, the effects of HGF on improving direct reprogramming of fibroblasts into EPCs by ETV2 may be an indirect one. This may mean that HGF does not participate in any signaling pathways to change the epigenetics which help fibroblasts acquire the EPC phenotype, but that HGF can stimulate the proliferation and maturation of the reprogrammed EPCs.

CONCLUSION

EPCs have been widely used in stem cell therapy and tissue engineering. Our study herein describes an enhancement of direct reprogramming of fibroblasts into induced EPCs by single viral vector of ETV2 in combination with HGF. The induced cells exhibited the functional phenotype of EPCs, including CD31 and VEGFR2 expression, gene profile related to EPCs, and capillary-like structure formation. The role of HGF may be to directly affect the reprogramming signaling pathway or indirectly stimulate proliferation of induced cells. Our findings demonstrate that HGF treatment is another approach to increase the efficacy of direct reprogramming of fibroblasts towards induced EPCs by single ETV2 vector.

Acknowledgements

This research was funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 106-YS.06-2013.37.

Competing Interests

The authors declare they have no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Amini, A.R., Laurencin, C.T., and Nukavarapu, S.P. (2012). Differential analysis of peripheral blood- and bone marrow-derived endothelial progenitor cells for enhanced vascularization in bone tissue engineering. *J Orthop Res* 30, 1507-1515.
- Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., and Isner, J.M. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *The EMBO journal* 18, 3964-3972.
- Cherqui, S., Kurian, S.M., Schussler, O., Hewel, J.A., Yates, J.R., 3rd, and Salomon, D.R. (2006). Isolation and angiogenesis by endothelial progenitors in the fetal liver. *Stem Cells* 24, 44-54.
- Choi, K.D., Yu, J., Smuga-Otto, K., Salvagiotto, G., Rehrauer, W., Vodyanik, M., Thomson, J., and Slukvin, I. (2009). Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. *Stem Cells* 27, 559-567.
- Ferreira, L.S., Gerecht, S., Shieh, H.F., Watson, N., Rupnick, M.A., Dallabrida, S.M., Vunjak-Novakovic, G., and Langer, R. (2007). Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle-like cells and form vascular networks in vivo. *Circulation research* 101, 286-294.
- Han, J.K., Chang, S.H., Cho, H.J., Choi, S.B., Ahn, H.S., Lee, J., Jeong, H., Youn, S.W., Lee, H.J., Kwon, Y.W., et al. (2014). Direct conversion of adult skin fibroblasts to endothelial cells by defined factors. *Circulation* 130, 1168-1178.
- Hirashima, M., Kataoka, H., Nishikawa, S., Matsuyoshi, N., and Nishikawa, S.-I. (1999). Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. *Blood* 93, 1253-1263.
- Hristov, M., Erl, W., and Weber, P.C. (2003). Endothelial progenitor cells: isolation and characterization. *Trends Cardiovasc Med* 13, 201-206.
- Ishizawa, K., Kubo, H., Yamada, M., Kobayashi, S., Suzuki, T., Mizuno, S., Nakamura, T., and Sasaki, H. (2004). Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. *Biochem Biophys Res Commun* 324, 276-280.
- Kalka, C., Masuda, H., Takahashi, T., Kalka-Moll, W.M., Silver, M., Kearney, M., Li, T., Isner, J.M., and Asahara, T. (2000). Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proceedings of the National Academy of Sciences* 97, 3422-3427.
- Kondo, M., Wagers, A.J., Manz, M.G., Prohaska, S.S., Scherer, D.C., Beilhack, G.F., Shizuru, J.A., and Weissman, I.L. (2003). Biology of hematopoietic stem cells and progenitors: implications for clinical application. *Annual review of immunology* 21, 759-806.
- Lee, S., Park, C., Han, J.W., Kim, J.Y., Cho, K., Kim, E.J., Kim, S., Lee, S.-J., An, H.J., Sin, M.Y., et al. (2014). Abstract 18205: Direct Reprogramming of Human Dermal Fibroblasts into Endothelial Cells Using a Single Transcription Factor. *Circulation* 130, A18205-A18205.
- Levenberg, S., Golub, J.S., Amit, M., Itskovitz-Eldor, J., and Langer, R. (2002). Endothelial cells derived from human embryonic stem cells. *Proceedings of the national Academy of Sciences* 99, 4391-4396.
- Li, J., Huang, N.F., Zou, J., Laurent, T.J., Lee, J.C., Okogbaa, J., Cooke, J.P., and Ding, S. (2013). Conversion of human fibroblasts to functional endothelial cells by defined factors. *Arterioscler Thromb Vasc Biol* 33, 1366-1375.
- Margariti, A., Winkler, B., Karamariti, E., Zampetaki, A., Tsai, T.N., Baban, D., Ragoussis, J., Huang, Y., Han, J.D., Zeng, L., et al. (2012). Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. *Proc Natl Acad Sci U S A* 109, 13793-13798.
- Masek, L.C., and Sweetenham, J.W. (1994). Isolation and culture of endothelial cells from human bone marrow. *Br J Haematol* 88, 855-865.
- Mead, L.E., Prater, D., Yoder, M.C., and Ingram, D.A. (2008). Isolation and characterization of endothelial progenitor cells from human blood. *Curr Protoc Stem Cell Biol* Chapter 2, Unit 2C 1.
- Morita, R., Suzuki, M., Kasahara, H., Shimizu, N., Shichita, T., Sekiya, T., Kimura, A., Sasaki, K., Yasukawa, H., and Yoshimura, A. (2015). ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells. *Proc Natl Acad Sci U S A* 112, 160-165.
- Park, C., Lee, T.J., Bhang, S.H., Liu, F., Nakamura, R., Oladipupo, S.S., Pitha-Rowe, I., Capoccia, B., Choi, H.S., Kim, T.M., et al. (2016). Injury-Mediated Vascular Regeneration Requires Endothelial ER71/ETV2. *Arterioscler Thromb Vasc Biol* 36, 86-96.
- Sanada, F., Taniyama, Y., Azuma, J., Iekushi, K., Dosaka, N., Yokoi, T., Koibuchi, N., Kusunoki, H., Aizawa, Y., and Morishita, R. (2009). Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. *Hypertension* 53, 77-82.
- Schroder, K., Schutz, S., Schloffel, I., Batz, S., Takac, I., Weissmann, N., Michaelis, U.R., Koyanagi, M., and Brandes, R.P. (2011). Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. *Antioxid Redox Signal* 15, 915-923.

- Schupp, M.O., Waas, M., Chun, C.Z., and Ramchandran, R. (2014). Transcriptional inhibition of *etv2* expression is essential for embryonic cardiac development. *Dev Biol* 393, 71-83.
- Shi, X., Richard, J., Zirbes, K.M., Gong, W., Lin, G., Kyba, M., Thomson, J.A., Koyano-Nakagawa, N., and Garry, D.J. (2014). Cooperative interaction of *Etv2* and *Gata2* regulates the development of endothelial and hematopoietic lineages. *Dev Biol* 389, 208-218.
- Song, M.B., Yu, X.J., Zhu, G.X., Chen, J.F., Zhao, G., and Huang, L. (2009). Transfection of HGF gene enhances endothelial progenitor cell (EPC) function and improves EPC transplant efficiency for balloon-induced arterial injury in hypercholesterolemic rats. *Vascul Pharmacol* 51, 205-213.
- Takahashi, K., and Yamanaka, S. (2006). Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* 126, 663-676.
- Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M., Isner, J.M., and Asahara, T. (1999). Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nature medicine* 5, 434-438.
- Urbich, C., and Dimmeler, S. (2004). Endothelial progenitor cells characterization and role in vascular biology. *Circulation research* 95, 343-353.
- Van Pham, P., Vu, N.B., Nguyen, H.T., Huynh, O.T., and Truong, M.T. (2016). Significant improvement of direct reprogramming efficacy of fibroblasts into progenitor endothelial cells by ETV2 and hypoxia. *Stem Cell Res Ther* 7, 104.
- Vittet, D., Prandini, M.-H., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., and Dejana, E. (1996). Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. *Blood* 88, 3424-3431.
- Wang, Z.Z., Au, P., Chen, T., Shao, Y., Daheron, L.M., Bai, H., Arzigian, M., Fukumura, D., Jain, R.K., and Scadden, D.T. (2007). Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. *Nature biotechnology* 25, 317-318.
- Yu, X., Song, M., Chen, J., Zhu, G., Zhao, G., Wang, H., and Hunag, L. (2010). Hepatocyte growth factor protects endothelial progenitor cell from damage of low-density lipoprotein cholesterol via the PI3K/Akt signaling pathway. *Mol Biol Rep* 37, 2423-2429.
- Zhou, Y.J., Wang, J.H., and Zhang, J. (2006). Hepatocyte growth factor protects against apoptosis induced by advanced glycation end products in endothelial cells. *Chin Med Sci J* 21, 6-10.
- Zhou, Y.J., Yang, H.W., Wang, X.G., and Zhang, H. (2009). Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. *Life Sci* 85, 670-677.
- Zhu, G., Huang, L., Song, M., Yu, Z., Wu, X., Zhao, X., Jin, J., Zhao, G., Chen, J., and Yu, S. (2010). Over-expression of hepatocyte growth factor in smooth muscle cells regulates endothelial progenitor cells differentiation, migration and proliferation. *Int J Cardiol* 138, 70-80.
- Cite this article as:**
Pham, P., Vu, N., Truong, M., Huynh, O., Nguyen, H., & Phan, N. (2016). Hepatocyte growth factor improves direct reprogramming of fibroblasts towards endothelial progenitor cells via ETV2 transduction. *Biomedical Research and Therapy*, 3(9): 836-843.